Foghorn Therapeutics (FHTX) Total Current Liabilities (2019 - 2026)

Foghorn Therapeutics' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $64.4 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 9.68% year-over-year to $64.4 million; the TTM figure through Mar 2026 stood at $64.4 million (down 9.68% YoY), while the FY2025 annual figure was $59.7 million, down 10.82% from the prior year.
• Total Current Liabilities was $64.4 million for Q1 2026 at Foghorn Therapeutics, up from $59.7 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $85.1 million in Q3 2025 to a low of $48.0 million in Q2 2022.
• Historically, Total Current Liabilities has averaged $59.7 million across 5 years, with a median of $56.6 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities surged 195.39% in 2022, then declined 10.82% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $55.2 million in 2022, then grew by 5.85% to $58.4 million in 2023, then climbed by 14.64% to $67.0 million in 2024, then retreated by 10.82% to $59.7 million in 2025, then advanced by 7.81% to $64.4 million in 2026.
• The last three Total Current Liabilities figures came in at $64.4 million (Q1 2026), $59.7 million (Q4 2025), and $85.1 million (Q3 2025), per Business Quant data.